Point Biopharma Global Stock Total Asset
POINT Biopharma Global fundamentals help investors to digest information that contributes to POINT Biopharma's financial success or failures. It also enables traders to predict the movement of POINT Stock. The fundamental analysis module provides a way to measure POINT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to POINT Biopharma stock.
POINT |
POINT Biopharma Global Company Total Asset Analysis
POINT Biopharma's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current POINT Biopharma Total Asset | 578.32 M |
Most of POINT Biopharma's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, POINT Biopharma Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
CompetitionBased on the latest financial disclosure, POINT Biopharma Global has a Total Asset of 578.32 M. This is 92.31% lower than that of the Biotechnology sector and 70.73% lower than that of the Health Care industry. The total asset for all United States stocks is 98.04% higher than that of the company.
POINT Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses POINT Biopharma's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of POINT Biopharma could also be used in its relative valuation, which is a method of valuing POINT Biopharma by comparing valuation metrics of similar companies.POINT Biopharma is currently under evaluation in total asset category among its peers.
POINT Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 5.45 X | |||
| Revenue | 226.58 M | |||
| EBITDA | 127.32 M | |||
| Net Income | 98.29 M | |||
| Cash And Equivalents | 199.43 M | |||
| Cash Per Share | 2.21 X | |||
| Total Debt | 3.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.90 X | |||
| Book Value Per Share | 4.01 X | |||
| Cash Flow From Operations | 183.52 M | |||
| Short Ratio | 0.98 X | |||
| Earnings Per Share | 1.10 X | |||
| Target Price | 12.5 | |||
| Number Of Employees | 129 | |||
| Beta | -0.003 | |||
| Market Capitalization | 1.33 B | |||
| Total Asset | 578.32 M | |||
| Retained Earnings | 39.01 M | |||
| Working Capital | 451.08 M | |||
| Net Asset | 578.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |